Coordinated gastric and sphincter motility evoked by intravenous CCK-8 as monitored by ultrasonomicrometry in rats.
Gastric and sphincter motility evoked by intravenous injection of CCK-8 were investigated in urethane-anesthetized rats. Digital ultrasonomicrometry was used to monitor pyloric (PYL), antral (ANT), corpus (COR), and lower esophageal sphincter (LES) movements while simultaneously measuring intragastric pressure (IGP) and, in some experiments, subdiaphragmatic intraesophageal pressure (sIEP). Intracrystal distances (ICD) were measured continuously between pairs of piezoelectric crystals affixed to the serosa of PYL, ANT, COR (circular and longitudinal), and LES. Consecutive intravenous injections of CCK-8 (0.3, 1, and 3 microg/kg) at 30-min intervals caused dose-dependent simultaneous tonic contractions of PYL and ANT, LES opening, and drops in IGP with peak changes at 3 microg/kg of -17.9 +/- 2.1, -7.7 +/- 2.5, 6.5 +/- 1.4, and -29.2 +/- 3.8%, respectively, whereas intravenous saline had no effect. Rhythmic contractile activity was inhibited by CCK-8. COR responses were not significantly different from vehicle controls for most metrics, and the direction of response for circular COR varied between preparations, although not for repeated trials in a single preparation. During the LES response to CCK-8, sIEP rose in parallel with drops in IGP, indicating formation of a common cavity. Recovery of LES ICD after intravenous CCK occurred more rapidly than recovery of PYL ICD, suggesting the importance of preventing simultaneous patency of gastroesophageal and gastroduodenal passages. The CCK(A) receptor antagonist devazepide (500 microg/kg intravenous) inhibited motion responses evoked by intravenous CCK-8. These data revealed CCK-8-induced gastric and sphincter activity consistent with retropulsion of gastric content.
Adelson
David W
DW
Digestive Diseases Research Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90073, USA. dadelson@ucla.edu
Million
Mulugeta
M
Kanamoto
Koki
K
Palanca
Tiffany
T
Taché
Yvette
Y
D000818:Animals; D020109:Devazepide / Q000494:pharmacology; D004106:Dilatation / Q000379:methods; D004943:Esophagogastric Junction / Q000000981:diagnostic imaging* / Q000502:physiology*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006727:Hormone Antagonists / Q000494:pharmacology; D007267:Injections; D007275:Injections, Intravenous; D008297:Male; D008365:Manometry; D011312:Pressure; D051381:Rats; D017207:Rats, Sprague-Dawley; D012844:Sincalide / Q000008:administration & dosage*; D012965:Sodium Chloride / Q000008:administration & dosage; D013270:Stomach / Q000000981:diagnostic imaging* / Q000502:physiology*; D013997:Time Factors; D014463:Ultrasonography
D006727:Hormone Antagonists; D012965:Sodium Chloride; D020109:Devazepide; D012844:Sincalide